Lv1
38 积分 2023-08-31 加入
[177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
19小时前
求助中
Performance of PSMA-PET/CT as verified by bone biopsy for diagnosing osseous metastases of prostate cancer
13天前
已完结
Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer
1个月前
已完结
Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system (‘Pro-PET’ score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis
1个月前
已完结
Safety and Efficacy of Lutetium‐177 PSMA Radioligand Therapy in Metastatic Castration‐Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study)
1个月前
已完结
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
1个月前
已完结
Assessing PSMA Receptor Availability Using 68Ga-PSMA-11 PET/CT Following 177Lu-PSMA-617 Therapy Administration
1个月前
已关闭
99mTc-PSMA SPECT/CT Versus 68Ga-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer
1个月前
已完结
Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy
2个月前
已完结
Initial Results and Clinical Experiences of [ 177 Lu]Lu-FAP-2286 for Pleural Metastases: A Single-Center Retrospective Study
2个月前
已关闭
皖公网安备34019202002308
